These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 37517376)

  • 1. Efficacy and safety of tramadol in the treatment of opioid withdrawal: A meta-analysis of randomized controlled trials.
    Padhan M; Maiti R; Mohapatra D; Mishra BR
    Addict Behav; 2023 Dec; 147():107815. PubMed ID: 37517376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine for managing opioid withdrawal.
    Gowing L; Ali R; White JM; Mbewe D
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological therapies for management of opium withdrawal.
    Rahimi-Movaghar A; Gholami J; Amato L; Hoseinie L; Yousefi-Nooraie R; Amin-Esmaeili M
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007522. PubMed ID: 29929212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid treatment for opioid withdrawal in newborn infants.
    Zankl A; Martin J; Davey JG; Osborn DA
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD002059. PubMed ID: 34231914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
    Mattick RP; Breen C; Kimber J; Davoli M
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD002207. PubMed ID: 24500948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002025. PubMed ID: 15495026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha₂-adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White JM
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD002024. PubMed ID: 27140827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2006 Apr; (2):CD002025. PubMed ID: 16625553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White JM
    Cochrane Database Syst Rev; 2009 Jul; (3):CD002025. PubMed ID: 19588330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid antagonists with minimal sedation for opioid withdrawal.
    Gowing L; Ali R; White JM
    Cochrane Database Syst Rev; 2017 May; 5(5):CD002021. PubMed ID: 28553701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha2-adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell MF; Ali R; White JM
    Cochrane Database Syst Rev; 2014 Mar; (3):CD002024. PubMed ID: 24683051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid agonist treatment for pharmaceutical opioid dependent people.
    Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
    Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded table: Some drugs for management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):e144-e146. PubMed ID: 30133422
    [No Abstract]   [Full Text] [Related]  

  • 16. Maintenance agonist treatments for opiate-dependent pregnant women.
    Minozzi S; Amato L; Jahanfar S; Bellisario C; Ferri M; Davoli M
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD006318. PubMed ID: 33165953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sedatives for opioid withdrawal in newborn infants.
    Zankl A; Martin J; Davey JG; Osborn DA
    Cochrane Database Syst Rev; 2021 May; 5(5):CD002053. PubMed ID: 34002380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis.
    Meader N
    Drug Alcohol Depend; 2010 Apr; 108(1-2):110-4. PubMed ID: 20074867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):137-141. PubMed ID: 30133420
    [No Abstract]   [Full Text] [Related]  

  • 20. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.
    Umbricht A; Hoover DR; Tucker MJ; Leslie JM; Chaisson RE; Preston KL
    Drug Alcohol Depend; 2003 Apr; 69(3):263-72. PubMed ID: 12633912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.